Johnson & Johnson Services, Inc.
VC Fund
New Brunswick, United States
Johnson & Johnson Services, Inc. is a VC fund in New Brunswick focused on Health Care and Biotechnology. Johnson & Johnson's research and development, manufacturing, and sale of healthcare products include pharmaceuticals, medical devices, and diagnostics. The company aims to improve access and create healthier communities.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 41%
Last updated:
For AI agents: llms.txt
Industries Johnson & Johnson Services, Inc. invests in
Stages Johnson & Johnson Services, Inc. invests in
Countries Johnson & Johnson Services, Inc. invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 22 contacts → | |||
Round size
- Seed
- $100k–$15M
- Grant
- $19k–$800k
Investment Focus
Industry
- Health Care 26 (70%)
- Biotechnology 6 (16%)
- Information Technology 5 (14%)
- Medical 4 (11%)
- mHealth 4 (11%)
Stage
- Grant 9 (24%)
- Funding Round 7 (19%)
- Seed 5 (14%)
- Series B 4 (11%)
- Post-IPO Equity 3 (8%)
Country
- United States 22 (59%)
- Uganda 2 (5%)
- The Netherlands 2 (5%)
- China 1 (3%)
- Japan 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alice Lin Fabiano
Director, Worldwide Corporate Giving
|
Director, Worldwide Corporate Giving | Total investments: 0 | Find email | |
Anne Mulcahy
Lead Director of the Board
|
Lead Director of the Board | Total investments: 0 | Find email | |
Charles Prince
Board of Directors
|
Board of Directors | Total investments: 0 | Find email | |
Dominic J. Caruso
Vice President, Finance and Chief Financial Officer
|
Vice President, Finance and Chief Financial Officer | Total investments: 0 | Find email | |
Hirak Parikh
Associate, Venture Investments
|
Associate, Venture Investments | Total investments: 3 | Find email | |
| See all 22 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sail Biomedicines is a flagship pioneering company that is developing tomorrow's medicines today using life's language. Sail's platform combines first-in-class translatable circular RNA technology (Endless RNATM or eRNA) with unique programmable nanoparticles based on natural components to thoroughly program medications for the firsttime. | $465M / Corporate Round / Jul 29, 2026 | ||
| The American College of Cardiology, a 49000-member nonprofit medical society. | Grant / Jul 22, 2026 | ||
| Sensori is spearheading the trend for social beverages that include nootropics and adaptogens that have been clinically studied to produce a feel-good condition. Sensori provides an uncompromising, all-natural means of connecting, relaxing, and embracing the human experience. | $100K / Seed / Aug 06, 2025 | ||
| Alessa Therapeutics is a pre-clinical stage company that develops localized treatments for solid organ disease. | $15M / Seed / Dec 12, 2024 | ||
| Tempo Therapeutics develops materials that are immune stealth, minimally invasive, and precision-engineered for regenerative medicine. It provides power to regenerative medicine, providing materials that evade the typical host immune rejection response to build synthetic tissue hybrids from skin to bone to heart to brain. | Venture - Series Unknown / Sep 12, 2024 | ||
| Ready, Set, Food! makes it easy for parents reduce their baby's risk of developing peanut, egg, and milk allergies by up to 80% with our gentle, daily system. | $6.9M / Series A / Jan 01, 2024 | ||
| mClinica develops mobile platforms that strengthen the pharmaceutical supply chain, generate data, improve patient adherence to medication, and build the capacity of the pharmacy workforce. Since 2017, mClinica has connected 150,000 pharmacy professionals and 40,000 pharmacies through a single digital channel. Their users reach approximately 150million patients each month. mClinica currently operates across Indonesia, Philippines, Vietnam, Cambodia, Thailand, Malaysia, and Singapore with capacity for expansion. Their team is composed of over 120 team members including experts in public health, data science, and pharmacy. mClinica is supported by impact investors like the Global Innovation Fund (backed by USAID, UKAID, DFAT, Swedish Government, and the Omidyar Network) and Patamar Capital (formerly Unitus Impact) as well as other investors from the US, Europe, and Asia. mClinica implements projects both digitally and on the ground to connect the world’s pharmacies and transform global health. mClinica follows a social enterprise business model in which they seek double-bottom line returns – maximizing both financial returns and social impact.mClinica’s rapid growth and success is increasingly recognized. mClinica was the recipient of the Data Driven Apps Award of the World Government Summit in 2019, USAID-FHI360 Data for Resilience Award, Pierre Fabre Foundation Prize for eHealth Innovation, and Hack Osaka. The company has consistently been recognized as one of the most innovative startups in healthcare in Asia Pacific. | $10M / Series B / Feb 09, 2023 | ||
| Ready, Set, Food! makes it easy for parents reduce their baby's risk of developing peanut, egg, and milk allergies by up to 80% with our gentle, daily system. | $20M / Series A / Jan 01, 2022 | ||
| IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest block-chain encrypted repository of indigenous and diasporic African clinical and multi-omics data for disease prevention/detection, drug discovery and development, clinical disease management, and precisionhealth equity. | $175K / Grant / Dec 31, 2021 | ||
| Lucia Health Guidelines provides intelligent solutions for atrial fibrillation management and stroke prevention. | $100K / Grant / Aug 31, 2021 | ||
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Johnson & Johnson Services, Inc. invest in?
Johnson & Johnson Services, Inc. invests primarily in Health Care, Biotechnology and Information Technology startups, most often at Grant and Funding Round stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Johnson & Johnson Services, Inc. invest in?
Johnson & Johnson Services, Inc. typically joins rounds of $100k–$15M at Seed and $19k–$800k at Grant. These are whole funding-round sizes, not Johnson & Johnson Services, Inc.'s own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Johnson & Johnson Services, Inc. took part in.
How do I contact Johnson & Johnson Services, Inc.?
Public channels for Johnson & Johnson Services, Inc. include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Johnson & Johnson Services, Inc.?
The team at Johnson & Johnson Services, Inc. includes Alice Lin Fabiano (Director, Worldwide Corporate Giving), Anne Mulcahy (Lead Director of the Board) and Charles Prince (Board of Directors), among 22 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
